Company wished to rapidly understand whether their recently launched product demonstrated effectiveness in the real-world

Given the required timeframe, concluded that generating new data/prospective study was not feasible. Hence, shortlisted potential databases/registries already licensed that would have the required patient exposure and outcomes of interest. Analysed company’s existing UK THIN and US Truven MarketScan databases using R

Completed preliminary analysis in two weeks, providing rapid guidance on further activities and study designs